
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Cardinal Health (CAH) navigates a dynamic healthcare market with strategic acquisitions and earnings acceleration, facing challenges from contract expiry and macro factors.
Cardinal Health (CAH) navigates headwinds with strategic acquisitions and a focus on specialty markets driving growth. Analyst upgrades and dividends reinforce stability.
Cardinal Health's Q2 earnings beat estimates, driven by strategic acquisitions and strong pharmaceutical segment performance. However, the OptumRx contract expiry poses challenges.
Cardinal Health (CAH) navigates Q2 earnings beat amid OptumRx headwinds, strategic acquisitions, and cash flow concerns. Analysts raise targets, but challenges persist.
A comprehensive analysis of Cardinal Health's Q2 2025 earnings report, detailing segment performance, dividend news, strategic acquisitions, and market trends.
An in-depth update on CAH Q2 2025 earnings, strategic moves, and dividend news that shapes its market outlook.